Lunit Plans Five AI Biomarker Abstracts for ESMO
Lunit announced on Oct. 1 that it will participate in the '2026 European Society for Medical Oncology (ESMO 2026)' held in Madrid, Spain, from Oct. 23 to 27 to present five research abstracts utilizing its AI biomarker platform, 'Lunit SCOPE'.Lunit will unveil a PD-L1 evaluation study utilizing surg
Lunit, an AI biomarker platform, has announced its participation in the 2026 European Society for Medical Oncology (ESMO 2026) conference in Madrid, Spain, from October 23 to 27. The company will present five research abstracts utilizing its AI technology. One study focuses on PD-L1 evaluation using surgical specimens from non-small cell lung cancer patients, comparing Lunit SCOPE's results with those of a pathologist.
The company will also showcase its involvement in the AIforHER project led by the French cancer center ICO, which aims to develop optimal diagnostic models for breast cancer HER2 analysis. Furthermore, Lunit will present findings from studies analyzing the prognostic significance of endothelial cells and KRAS mutation subtypes in pancreatic ductal adenocarcinoma, as well as the prognostic value of tertiary lymphoid structures for pan-cancer patients who have received immunotherapy.
CEO Suh Beom-seok emphasized that the company will share global research achievements across various cancer types at the conference, aiming to contribute to customized treatment strategies for patients by accurately analyzing tumors and their surrounding environments.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
